| Literature DB >> 25883590 |
Ahmed K Al Atya1, Karima Drider-Hadiouche2, Rozenn Ravallec1, Amadine Silvain3, Anne Vachee2, Djamel Drider1.
Abstract
107 bacterial isolates with Gram positive staining and negative catalase activity, presumably assumed as lactic acid bacteria, were isolated from samples of meconium of 6 donors at Roubaix hospital, in the north of France. All these bacterial isolates were identified by MALDI-TOF mass spectrometry as Enterococcus faecalis. However, only six isolates among which E. faecalis 14, E. faecalis 28, E. faecalis 90, E. faecalis 97, and E. faecalis 101 (obtained from donor 3), and E. faecalis 93 (obtained from donor 5) were active against some Gram-negative bacteria and Gram-positive bacteria , through production of lactic acid, and bacteriocin like inhibitory substances. The identification of these isolates was confirmed by 16rDNA sequencing and their genetic relatedness was established by REP-PCR and pulsed field gel electrophoresis methods. Importantly, the aforementioned antagonistic isolates were sensitive to various classes of antibiotics tested, exhibited high scores of coaggregation and hydrophobicity, and were not hemolytic. Taken together, these properties render these strains as potential candidates for probiotic applications.Entities:
Keywords: Enterococcus faecalis; antagonism; anti-Staphylococcus activity; enterocins; meconium
Year: 2015 PMID: 25883590 PMCID: PMC4382979 DOI: 10.3389/fmicb.2015.00227
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Inhibitory activity before neutralization of the cell-free supernatant (BN) and after the neutralization of the cell-free supernatant (AN).
| Indicator strain | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BN | AN | BN | AN | BN | AN | BN | AN | BN | AN | BN | AN | |
| 7.15 ± 0.2 | 5.8 ± 0.4 | 6.0 ± 0.2 | 3.6 ± 0.84 | 5.9 ± 0.5 | 3.55 ± 08 | 6.6 ± 0.1 | 4.0 ± 0.1 | 6.25 ± 0.4 | 3.70 ± 0.6 | 6.5 ± 0.5 | 3.3 ± 0.24 | |
| 7.65 ± 0.2 | 6.3 ± 0.4 | 6.1 ± 0.1 | 4.8 ± 0.56 | 6.2 ± 0.2 | 4.3 ± 0.6 | 5.7 ± 0.1 | 4.1 ± 0.5 | 6.3 ± 0.9 | 4.20 ± 0.2 | 7.5 ± 0.7 | 5.6 ± 0.8 | |
| 7.7 ± 0.4 | 6.2 ± 0.1 | 6.8 ± 0.2 | 4.7 ± 0.3 | 7.3 ± 0.2 | 4.8 ± 0.3 | 6.2 ± 46 | 3.8 ± 0.1 | 5.5 ± 0.7 | 2.60 ± 0.5 | 7.2 ± 0.2 | 3.3 ± 0.24 | |
| 4.8 ± 0.3 | 3.6 ± 0.8 | 6.0 ± 0.2 | 5.6 ± 0.47 | 6.1 ± 0.1 | 5.5 ± 0.6 | 5.7 ± 0.9 | 4.9 ± 0.9 | 4.6 ± 0.21 | 4.50 ± 0.5 | 4.8 ± 0.2 | 3.6 ± 0.3 | |
| Methicillin-resistant | 2.6 ± 0.7 | 0 | 3.2 ± 0.8 | 0 | 2.8 ± 0.5 | 0 | 2.5 ± 0.4 | 0 | 2.3 ± 0.55 | 0 | 2.4 ± 0.6 | 0 |
| 7.6 ± 0.56 | 6.1 ± 0.8 | 5.2 ± 0.4 | 4.20 ± 0.6 | 5.1 ± 0.3 | 4.2 ± 0.6 | 5.8 ± 3 | 4.3 ± 1.0 | 4.7 ± 0.14 | 5.10 ± 0.9 | 4.5 ± 0.4 | 5.0 ± 0.80 | |
| 6.4 ± 0.2 | 0 | 4.85 ± 0.2 | 0 | 4.5 ± 0.5 | 0 | 4.3 ± 0.7 | 0 | 3.9 ± 0.25 | 0 | 4.15 ± 0. | 0 | |
| 6.65 ± 0.3 | 0 | 5.65 ± 0.3 | 0 | 4.7 ± 0.1 | 0 | 4.6 ± 0.4 | 2.1 ± 0.3 | 3.75 ± 0.1 | 0 | 4.7 ± 0.1 | 2.55 ± 0.20 | |
| 5.4 ± 0.3 | 0 | 5.95 ± 0.5 | 0 | 6.25 ± 0 | 0 | 3.9 ± 0.1 | 0 | 4.45 ± 0.4 | 0 | 5.0 ± 15 | 0 | |
| 5.7 ± 0.3 | 0 | 5.15 ± 0.1 | 0 | 4.7 ± 0.7 | 0 | 5.3 ± 0.7 | 0 | 4.55 ± 0.0 | 0 | 4.15 ± 0.0 | 0 | |
| 5.8 ± 0.4 | 0 | 5.0 ± 0.25 | 0 | 5.6 ± 0.5 | 2.5 ± 0.3 | 5.5 ± 0.5 | 0 | 4.4 ± 0.15 | 0 | 6.2 ± 0.1 | 2.6 ± 0.20 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Autoaggregation and hydrophobicity percentages of antagonistic meconium enterococci.
| Isolates | Autoaggregation (%) | Hydrophobicity (%) |
|---|---|---|
| 49 ± 0.47 | 47 ± 0.8 | |
| 44 ± 1.6 | 45.6 ± 0.47 | |
| 35 ± 1.24 | 41 ± 1.2 | |
| 44.6 ± 1.8 | 46.3 ± 1.2 | |
| 41 ± 1.24 | 34 ± 1.4 | |
| 45 ± 1.6 | 43 ± 0.94 | |
| 45.6 ± 0.1.2 | 42.3 ± 0.9 |
Antibiotic susceptibility of antagonistic isolates.
| Antibiotics MIC: mg/l | ||||||
|---|---|---|---|---|---|---|
| Ampicillin | S ( ≤ 2) | S ( ≤ 2) | S ( ≤ 2) | S ( ≤ 2) | S ( ≤ 2) | S ( ≤ 2) |
| Gentamicin (high level) | S | S | S | S | S | S |
| Kanamycin (high level) | S | S | S | S | S | S |
| Streptomycin (high level) | S | S | S | S | S | S |
| Levofloxacin | S (1) | S (1) | S (1) | S (1) | S (1) | S (1) |
| Moxifloxacin | S ( ≤ 0.25) | S ( ≤ 0.25) | S ( ≤ 0.25) | S ( ≤ 0.25) | S ( ≤ 0.25) | S ( ≤ 0.25) |
| Clindamycin | R ( ≥ 8) | R ( ≥ 8) | R ( ≥ 8) | R ( ≥ 8) | R ( ≥ 8) | R ( ≥ 8) |
| Linezolid | S (2) | S (2) | S (2) | S (2) | S (2) | S (2) |
| Teicoplanin | S ( ≤ 0.5) | S ( ≤ 0.5) | S ( ≤ 0.5) | S ( ≤ 0.5) | S ( ≤ 0.5) | S ( ≤ 0.5) |
| Vancomycin | S (1) | S (1) | S (1) | S (2) | S (1) | S (2) |
| Tetracyclin | S ( ≤ 1) | S ( ≤ 1) | S ( ≤ 1) | S ( ≤ 1) | S ( ≤ 1) | S ( ≤ 1) |
| Nitrofurantoin | S ( ≤ 16) | S ( ≤ 16) | S ( ≤ 16) | S ( ≤ 16) | S ( ≤ 16) | S ( ≤ 16) |
| Chloramphenicol | S (8) | S (8) | S (8) | S (8) | S (8) | S (8) |
| Trimethoprime/sulfamethoxzole | S ( ≤ 10) | S ( ≤ 10) | S ( ≤ 10) | S ( ≤ 10) | S ( ≤ 10) | S ( ≤ 10) |
| Erythromycin | R ( ≥ 8) | I (4) | I (4) | R ( ≥ 8) | I (4) | I (4) |
Antibiotic susceptibility of antagonistic isolates.
| Antibiotics MIC: mg/l | ||||||
|---|---|---|---|---|---|---|
| Ampicillin | S (0.75) | S (0.75) | S (0.75) | S (0.75) | S (0.38) | S (0.38) |
| Gentamicin (high level) | S | S | S | S | S | S |
| Kanamycin (high level) | S | S | S | S | S | S |
| Streptomycin (high level) | S | S | S | S | S | S |
| Levofloxacin | S (1) | S (1) | S (1) | S (1) | S (1) | S (1) |
| Moxifloxacin | S | S | S | S | S | S |
| Clindamycin | R | R | R | R | R | R |
| Linezolid | S (2) | S (1) | S (1) | S (1.5) | S (1.5) | S (2) |
| Teicoplanin | S (0.25) | S (0.25) | S (0.25) | S (0.25) | S (0.25) | S (0.25) |
| Vancomycin | S (2) | S (1) | S (1) | S (1) | S (2) | S (2) |
| Tetracyclin | S | S | S | S | S | S |
| Nitrofurantoin | S | S | S | S | S | S |
| Chloramphenicol | S | S | S | S | S | S |
| Trimethoprime/sulfamethoxzole | S | S | S | S | S | S |
| Erythromycin | R (2) | I (2) | I (1) | R (1.5) | I (1) | I (1.5) |